zolbetuximab
astellas
[]
#spotlight presented at #gi23 improved pfs w zolbetuximab/mfolfox6 vs placebo/mfolfox6 (med 10.6m vs 8.7m) for patients w la or mg/gej gastric cancer w cldn.18.2+/her2- disease os also improved (hr 0.75, p=0.0053), benefit seen beyond 8m 
Radiation Oncologist at the Princess Margaret Cancer Centre. 

Assistant Professor at the University of Toronto.

Tweets are my own.